Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose Disposal

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02006459

Acronym

Px-GIGD

Enrollment

Registered

2013-12-10

Start date

2013-09-30

Completion date

2015-10-31

Last updated

2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

Gastrointestinal-mediated glucose disposal, Total pancreatectomy, Incretin hormones, Glucagon

Brief summary

We want to investigate the mechanisms of extrapancreatic effects on gastrointestinal-mediated glucose disposal. In order to do so we will perform oral glucose tolerance tests and isoglycemic intravenous glucose infusions in total pancreatectomised patients and in healthy controls.

Detailed description

In the current project we wish to identify the possible contribution of extrapancreatic effects on gastrointestinal-mediated glucose disposal (GIGD). GIGD reflects the percentage of an individual's glucose disposal following oral glucose tolerance test (OGTT) which is caused by the oral route of glucose administration. In healthy subjects GIGD amounts to \ 60%. GIGD describes not only the impact of the incretin effect (insulinotropic substances released upon intestinal stimulation) but includes all factors affecting glucose disposal differently during oral vs. iv administration of glucose (including neural reflexes, activation of afferent nerves in the intestinal mucosa, differences in glucagon secretion, hepatic glucose production and first-pass hepatic uptake of glucose, differences in portal and venous blood glucose concentrations and/or at the present unknown factors. It is likely that the incretin effect (pancreatic effect) constitutes a major contributor to GIGD, but so far it has been impossible to discriminate between pancreatic and extrapancreatic mechanisms underlying GIGD

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Pancreatectomized patients * Caucasians above 18 years of age who have undergone total pancreatectomy * Normal haemoglobin * Informed consent Healthy Subjects * Normal fasting plasma glucose (FPG) and normal HbA1C (according to the World Health Organization (WHO) criteria) * Normal haemoglobin * Age above 18 years * Informed consent

Exclusion criteria

* Pancreatectomized patients * Inflammatory bowel disease * Operation within the last 3 months * Ongoing chemotherapy or chemotherapy within the last 3 months * Ostomy * Nephropathy (serum creatinine \>150 µM and/or albuminuria) * Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \>3×normal values) * Pregnancy and/or breastfeeding * Age above 80 years * Any condition that the investigator feels would interfere with trial participation Healthy Subjects * Diabetes mellitus (DM) * Prediabetes (impaired glucose tolerance and/or impaired FPG) * First degree relatives with DM * Inflammatory bowel disease * Intestinal resection and/or ostomy * Nephropathy (serum creatinine \>150 µM and/or albuminuria * Liver disease (ALAT and/or serum ASAT \>2×normal values) * Pregnancy and/or breastfeeding * Age above 80 years * Any condition that the investigator feels would interfere with trial participation

Design outcomes

Primary

Measure	Time frame	Description
Gastrointestinal-mediated glucose disposal (GIGD)	Calculated when the study days are all complete. approximately in 6month	GIGD will be calculated based on the amounts of glucose utilised during the two glucose administrations forms, OGTT and IIGI (GIGD (%) = 100%×(glucoseOGTT-glucoseIIGI)/glucoseOGTT)
plasma Glucagon	Glucagon will be measured at time points: -30,-15,0,10,20,30,50,70,90,120,150,180 min on all days.	—

Secondary

Measure	Time frame	Description
endogenous glucose production	Endogenous glucose production will be calculated based on blood samples at time points: -30,-15,0,10,20,30,50,70,90,120,150,180 min on all days.	calculated based on infusions of stable isotope marked glucose
Incretin Hormones	incretin hormone levels will be measured at time points: -30,-15,0,10,20,30,50,70,90,120,150,180 min on all days.	GIP, GLP-1
Satiety, hunger, appetite	Satiety, hunger and appetite will be measured at time points:0,30,60,90,120,150,180 min during each day.	Will be measured with visual analogue scales (VAS)

Countries

Denmark

Outcome results